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We present the case of a 68-year-old man with coronary artery disease and a history of
recurrent myocardial infarctions, having left ventricular ejection fraction 25% in NYHA
functional class III. The patient received a biventricular cardioverter-defibrillator (ICD)
Biotronik Lumax 340 HF-T in November 2008 from the primary prophylactic indication.
Remote monitoring using the Biotronik Home MonitoringTM (HM) system was activated
since device implantation. Up to April 2012 the patient received five shocks including 3
appropriate VF therapies and 2 inappropriate ICD shocks (due to T-wave oversensing and
atrial flutter degenerating to VF after ATPs). All arrhythmic events were promptly detected
by the HM system with a rapid consequent pharmacological and non-pharmacological
intervention (radiofrequency catheter ablation of atrial arrhythmia and reprogramming
the device). This case points out that prophylactic ICD implantation is a justifiable method
for the prevention of arrhythmic death in high-risk patients and HM significantly helps in
the early recognition of inappropriate ICD therapy.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
The issue of implantable cardioverter–defibrillator (ICD)
shocks, whether appropriate or inappropriate, not only has
an impact on the quality of patients‘ life but it also affects
mortality [1,2]. Therefore, one of the most beneficial effects of
remote monitoring in ICD patients is early shock detection.
We present a case where the Biotronik Home MonitoringTM
(HM) system has helped in therapeutic decision with conse-
quent significant reduction of inappropriate ICD shocks.ch Society of Cardiology.
, fax: þ420 543182205.
idova´), miroslav.novak@fn2. Case report
A 68-year-old man with coronary artery disease and a history
of recurrent myocardial infarctions, with a left ventricular
ejection fraction of 25% in NYHA functional class III, received
a biventricular ICD Lumax 340 HF-T in November 2008.
The indication for ICD implantation was the primary pro-
phylactic according to ACC/AHA/ESC guidelines [3].
Since implanting the device, the patient has been continu-
ously monitored by a HM system. He received the first ICDPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
usa.cz (M. Nova´k),
.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 8 1 – e 2 8 4ee282shock in June 2010 due to a T-wave oversensing leading to
inappropriate detection in the ventricular fibrillation (VF)
zone (Fig. 1). After T-wave oversensing suppression adjust-
ment the oversensing problem did not occur again. In July
2011 an atrial flutter was revealed by HM, anticoagulation and
antiarrhythmic therapy was initiated immediately at an extra
follow-up. In September 2011 the patient had an episode inFig. 1 – Online IEGM of VF episode—trans
Fig. 2 – Online IEGM of VT episode (pre-detection period)—atr
detected as a VT by the device and burst therapy is initiated.the ventricular tachycardia (VT) zone with repetitive
antitachycardia pacing (ATP) therapies (Fig. 2). The last ATP
induced VF and was resolved by the first ICD shock. According
to the intracardiac electrogram (IEGM) sent by the HM, the
tachycardia was caused by the atrial flutter with a 1:1 ventri-
cular response (Fig. 3). Soon after, the patient underwent
radiofrequency catheter ablation of the typical atrial flutter.ient T-wave oversensing is apparent.
ial arrhythmia with rapid ventricular response is wrongly
Fig. 3 – Online IEGM of VT episode (pre-termination period)—after delivering 5 ATPs because of supraventricular tachycardia,
the real VF was induced and properly treated by the ICD shock.
Fig. 4 – Chronological view of event ‘‘Recordings’’ (Holter) from the HM system.
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therapy did not occur. Nevertheless, another two VF episodes
in October 2011 and one VF episode in February 2012 emerged
(Fig. 4). IEGMs demonstrated proper detection and adequate
successful therapy by the device.3. Discussion
3The breakthrough MADIT II (The Multicenter Automatic Defi-
brillator Implantation Trial) study has proven that patients with
reduced left ventricular function after myocardial infarction are
at higher risk of sudden cardiac death due to ventriculararrhythmias. Therefore, the use of ICD significantly improves
survival among these patients [4]. Nonetheless, in 15% of
patients inappropriate therapy occurs during the first year after
implantation [5]. The main causes of the inappropriate therapy
are: atrial fibrillation/flutter, supraventricular tachycardias
including sinus tachycardia and inappropriate sensing. The risk
of T-wave oversensing is reported to be higher in Biotronik
devices compared to other manufacturers such as Guidant or
Medtronic [6]. It can be explained by the different sensing
algorithms among the manufacturers; however, further inves-
tigation in this field is needed.
Remote monitoring has been proven to be very useful in
reducing inappropriate ICD shocks, mostly in the case of lead
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 8 1 – e 2 8 4ee284failure and T-wave oversensing [7]. Furthermore, real-time
telemetry of patients with atrial arrhythmias helps the physi-
cian to react early and optimize the drug and device therapy or
to consider the indication of radiofrequency catheter ablation.4. Conclusion
Since implantation, from November 2008 to April 2012, the
patient received five ICD shocks in total – two inappropriate
(due to T-wave oversensing and atrial flutter which, after
several ATPs, degenerated to VF) and three appropriate VF
therapies. This case points out that prophylactic ICD implan-
tation is a justifiable method for the prevention of arrhythmic
death in high-risk patients, however, potential complications
must be taken into account, especially the risk of inadequate
ICD therapy. The Biotronik HM system allows early arrhyth-
mia detection by the IEGM evaluation, and, consequently, it
enables quick pharmacological and/or non-pharmacological
intervention.Acknowledgments
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